| HOME >> MEDICINE >> TECHNOLOGY |
(*) The MADRS scale measures the severity of a number of depressive symptoms including mood and sadness, tension, sleep, appetite, energy, concentration, suicidal ideation, and restlessness. The MADRS score decreases as depressive symptoms improve.(12)
(+) The CGI-S score refers to the global impression of the patient and requires clinical experience with the syndrome under assessment. The CGI improvement scale can be completed only following or during treatment. The concept of improvement refers to the clinical distance between the individual's current condition and that prior to the start of treatment.(12)
(++) The HAM-A rating scale consists of 14 items and measures the severity of symptoms such as anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, restlessness, and other physical symptoms.(12)
(S) HAM-A response is defined as greater than or equal to 50% decrease in HAM-A total score from baseline(4)
(**) HAM-A remission is defined as HAM-A total score less than or equal to 7.4
References:
(1) Weisler R, Joyce M, McGill L, et al. Extended release Quetiapine fumarate (quetiapine XR) monotherapy for major depressive disorder (MDD): a double-blind, placebo-controlled study [poster]. Presented at: The Annual Meeting of the American Psychiatric Association; May 3-8, 2008, Washington, D.C., USA.
(2) Datto C, Lam RW, Lepola U, et al. Double-blind study of extended release quetiapine fumarate (quetiapine XR) monotherapy for maintenance treatment of major depressive disorder (MDD) [poster]. Presented at: The Annual Meeting of the American Psychiatric Association; May 3-8,2008, Washington, D.C., USA.
(3) El-Khalili N, Joyce M, Atkinson S, et al. Adjunctive
extended-release quetiapine fumarate (quetiapine XR) in patients with major
depressive disorder and inadequate antidepressant response [poster].
Presented at:
'/>"/>
| SOURCE AstraZeneca Copyright©2008 PR Newswire. All rights reserved |